No acquisition but Roche/Chugai rejig alliance terms
This article was originally published in Scrip
After rumors of a planned Roche buy-out of Chugai failed to materialize, the two companies have instead restructured some of the key terms of their original 2001 strategic alliance, in a change that will give Roche broader access and rights to Chugai's pipeline.
You may also be interested in...
While Chugai’s satralizumab may not be odds on to win the race for approval, it may beat Alexion’s Soliris on ease of use with a regimen of subcutaneous application once a month versus Soliris’ fortnightly IV.
While the global health threat from the now officially named SARS-CoV-2 coronavirus has grown since the start of the quarterly earnings season in early February, even many of the companies reporting more recently do not appear overly concerned about potential business impact at this stage.
Highly promising results for a novel, easy to use form of CAR therapy, as early trial in hematologic malignancies shows a high response and low toxicity.